spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Blood Tests May Prevent Relapse in Breast Cancer Patients

The Royal Marsden NHS Foundation Trust

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients wil



An innovative trial to detect relapse in breast cancer patients with circulating tumour DNA (ctDNA) has opened at The Royal Marsden NHS Foundation Trust.

The first patients in the world with oestrogen receptor (ER) positive breast cancer have been recruited to the TRAK-ER trial and will have a blood test every three months, for up to three years, to detect their risk of cancer returning. If risk of relapse is indicated, their treatment will be altered to try and prevent relapse from happening.

The TRAK-ER trial, led by researchers at The Royal Marsden and The Institute of Cancer Research, London, will establish a circulating tumour DNA (ctDNA) surveillance programme for over 1,000 patients with ER positive breast cancer who are currently receiving hormone therapy to reduce their risk of cancer returning. The trial will be rolled out to 20 UK centers over the next six months.

Cancer cells release DNA into the bloodstream known as circulating tumour DNA (ctDNA). The blood tests used in the trial can detect very low levels of ctDNA in a blood sample, to help determine whether any cancer is present in the body. Very low levels of cancer found in the blood is known as molecular relapse, which indicates that the patient will eventually relapse. Therefore, testing a patient’s blood for ctDNA will allow clinicians to diagnose the return of cancer at the very earliest stage. Previous studies have shown that ctDNA blood tests can identify relapse several months or even years before it can be seen on a scan.

A blood sample and tumour material from each patient’s previous breast cancer surgery will be analysed to design a personalised ctDNA test for each individual on the trial. Following a blood test, if cancer is detected in a patient’s blood, but there is no evidence of cancer on scan, they will be randomly allocated one of two treatment options. One group will receive both palbociclib (IbranceTM) and fulvestrant (FaslodexTM), whilst the other group will be offered either a change in their standard hormone therapy or they will continue on the same hormone therapy they are currently taking. The trial will look to see if patients treated with palbociclib and fulvestrant are less likely to relapse compared to those receiving standard hormone therapies.

Principal investigator of the TRAK-ER trial, Professor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Head of the Ralph Lauren Centre for Breast Cancer Research at The Royal Marsden NHS Foundation Trust, said:
“The risk of relapse for ER positive breast cancer patients is spread out over many years after initial treatment, which is one of the reasons why scans aren't effective in trying to pick it up. Blood tests could become the standard way of following up with this group of patients, and if the trial produces encouraging results, this could revolutionise how we treat ER positive breast cancer patients in the future and hopefully save more lives.”

Robert Nussbaum, M.D., chief medical officer at Invitae, said:
“Using a highly sensitive, personalised liquid biopsy to detect nascent cancer recurrence enables escalated intervention when it can be most effective, or even curative, for patients. This study will lay the groundwork for better post-treatment monitoring and potentially life-extending treatment for patients with ER-positive breast cancer.”

Elaine Nangle, 41, from Reading, was diagnosed with stage three lobular breast cancer in March 2020. Following treatment which included chemotherapy, radiotherapy and a mastectomy, she received the news that she was cancer free and was given the opportunity to join the TRAK-ER trial at The Royal Marsden.

She said: “Being part of something that may be able to give me forewarning of relapse is incredible and just knowing that I’m being monitored so frequently gives me a huge safety net. When you finish cancer treatment it’s normal to feel like your safety net has been withdrawn, so I feel extremely lucky to be part of this trial. Anything that gives me a greater chance of being here for longer, and being well for longer, is amazing.”


Elaine with her three children

The trial is an independent research study led by The Royal Marsden and funded by Pfizer, Invitae and Le Cure. Trial specific lab work will take place at the Ralph Lauren Centre for Breast Cancer Research at The Royal Marsden. The Centre was funded by supporters of The Royal Marsden Cancer Charity, including a generous donation from Ralph Lauren.
phone 02073528171
web https://www.royalmarsden.nhs.uk/
email The Royal Marsden, Fulham Road, London, SW3 6JJ
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cherwell publishes new guide to EM best practice in compliance with revised Annex 1

Bicester, UK, 26th January 2023: Cherwell, specialists in cleanroom microbiology solutions for the pharmaceutical, healthcare and related industries, has published an update to its guide on “Environmental Monitoring Processes and Validation”, incorporating specific detail on the new version of EU GMP Annex 1. This aims to help sterile medicinal product manufacturers with reviewing and improving their Environmental Monitoring (EM) programs in preparation for compliance with the revised guidelines by August 2023.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement